Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/26086
Başlık: Fas and Fas Ligand expression and relationship with clinicopathologic parameters in pancreas cancer
Diğer Başlıklar: Pankreatik kanserde Fas ve Fas Ligand ekspresyonu ve klinikopatolojik parametrelerle ilişkisi
Yazarlar: Gönüllü, Güzin
Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.
0000-0002-9732-5340
Öztürk, Hülya
Evrensel, Türkkan
Manavoğlu, Osman
AAJ-1027-2021
57197115377
6603942124
6602587152
Anahtar kelimeler: Fas ligand protein
Pancreatic neoplasms
Immune escape
Tumor-cells
Colon-cancer
Lung-cancer
In-vivo
Apoptosis
Carcinoma
Cd95
Counterattack
Adenocarcinomas
General & internal medicine
Fas ligand
Pankreas kanseri
Yayın Tarihi: Haz-2009
Yayıncı: Ortadoğu Yayınları
Atıf: Gönüllü, G. vd. (2009). "Fas and Fas Ligand expression and relationship with clinicopathologic parameters in pancreas cancer". Türkiye Klinikleri Tıp Bilimleri Dergisi, 29(3), 584-588.
Özet: Objective: Fas (CD95/APO-1) and Fas Ligand (FasL) are important in the process of apoptosis in the immune system. Hereby, we aimed to examine the expression of Fas/FasL in pancreatic adenocarcinoma and chronic pancreatic tissue and its relation with clinicopathological characteristics using immunohistochemical studies. Material and Methods: Pancreatic adenocarcinoma (n=35) and chronic pancreatitis cases (n=25) under-went assessment for Fas and FasL expression using immunohistochemistry. Results: The cancer group consisted of 24 female and I I male patients, while the chronic pancreatitis group included 21 female and 4 male patients. All patients had been diagnosed with adenocarcinoma. According to the International Union Against Cancer (UICC) staging, 19 patients were classified as stage III (unresectable) and 16 patients had stage IV disease. All patients classified as stage III were revealed to have unresectable tumors intraoperatively. The loss of Fas expression was higher in pancreatic adenocarcinoma than in chronic pancreatitis (57.1% vs. 29.2%, p=0.034). FasL over-expression was higher in pancreatic adenocarcinoma than in chronic pancreatitis (57.1% vs. 26.1%, p=0.031). Cytoplasmic staining of Fas (77.1% vs. 22.9%, p=0.016) and FasL (61.1% vs. 38.9%, p=0.002) was higher than membranous staining. According to stages, loss of Fas expression was greater in stage IV when compared with stage III (73.9% vs. 25%, p=0.01). There was no significant relationship between Fas and the stage of cancer (p> 0.05). Furthermore, there was no correlation between Fas/FasL staining and age and sex (p> 0.05). Conclusion: In pancreatic adenocarcinoma, loss of Fas expression and Fas L over-expression were statistically significant.
URI: https://www.turkiyeklinikleri.com/article/en-fas-and-fas-ligand-expression-and-relationship-with-clinicopathologic-parameters-in-pancreas-cancer-54793.html
http://hdl.handle.net/11452/26086
ISSN: 1300-0292
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Öztürk_vd_2009.pdf199.44 kBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons